Zobrazeno 1 - 10
of 516
pro vyhledávání: '"Shukui, Qin"'
Autor:
Jiujie Cui, Shukui Qin, Yuhong Zhou, Shuang Zhang, Xiaofeng Sun, Mingjun Zhang, Jiuwei Cui, Weijia Fang, Kangsheng Gu, Zhihua Li, Jufeng Wang, Xiaobing Chen, Jun Yao, Jun Zhou, Gang Wang, Yuxian Bai, Juxiang Xiao, Wensheng Qiu, Bangmao Wang, Tao Xia, Chunyue Wang, Li Kong, Jiajun Yin, Tao Zhang, Xionghu Shen, Deliang Fu, Chuntao Gao, Huan Wang, Quanren Wang, Liwei Wang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-control
Externí odkaz:
https://doaj.org/article/7a7dcbcd35414399b2d9715ea43ed0fe
Autor:
Chenyu Mao, Ye He, Nong Xu, Haijiao Yan, Ningling Zhang, Gang Cheng, Hua Jiang, Minbin Chen, Yong Chen, Xiaoguang Wang, Yulan Gu, Peng Shen, Guifang Zhang, Jun Yan, Zhe Yang, Lifang Ding, Zhengxiang Han, Zhanggui Wang, Junqi Zhang, Weie Zheng, Jufeng Wang, Shukui Qin
Publikováno v:
Immunity, Inflammation and Disease, Vol 12, Iss 8, Pp n/a-n/a (2024)
Abstract Background Mecapegfilgrastim, a long‐acting granulocyte‐colony stimulating factor has been approved for reducing the incidence of infection, particularly febrile neutropenia (FN), in China. Objective We conducted a multicenter prospectiv
Externí odkaz:
https://doaj.org/article/6bb646b47975406790ad1a5a53c2c0f2
Autor:
Shukui Qin, Yusheng Wang, Jun Yao, Yanyan Liu, Tienan Yi, Yueyin Pan, Zhendong Chen, Xizhi Zhang, Jin Lu, Junyan Yu, Yanjun Zhang, Peng Cheng, Yong Mao, Jian Zhang, Meiyu Fang, Yanming Zhang, Jing Lv, Runzi Li, Ning Dou, Qian Tang, Jun Ma
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Chemotherapy-induced thrombocytopenia (CIT) increases the risk of bleeding, necessitates chemotherapy dose reductions and delays, and negatively impacts prognosis. Objectives: This study aimed to evaluate the efficacy and safety of hetrom
Externí odkaz:
https://doaj.org/article/c4de4394972447dea8a8e3e0d45c76e9
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Skin toxicities are the most common adverse events related to immunotherapy, such as reactive cutaneous capillary endothelial proliferation (RCCEP) following treatment with the anti-programmed cell death-1 antibody camrelizumab. Objective
Externí odkaz:
https://doaj.org/article/d679f28a42204440a68400c367707cd2
Publikováno v:
Journal of Pharmacological Sciences, Vol 152, Iss 2, Pp 69-75 (2023)
Objective: AST-3424 is a novel specific aldo-keto reductase 1C3 (AKR1C3) prodrug that releases a DNA alkylating reagent upon reduction by AKR1C3. This study aimed to evaluate the efficacy and safety of AST-3424 in patient-derived tumor xenograft (PDT
Externí odkaz:
https://doaj.org/article/4be4ad79cff343dc8b0d7602b9af2104
Autor:
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Publikováno v:
Liver Cancer (2024)
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR
Externí odkaz:
https://doaj.org/article/d6ae54a6e78a47678e598fa918d4b74a
Autor:
Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Publikováno v:
Liver Cancer (2024)
Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primar
Externí odkaz:
https://doaj.org/article/1bff88f17a9a48489c63b55f5e686340
Autor:
Shukui Qin, Weijia Fang, Zhenggang Ren, Shuangyan Ou, Ho Yeong Lim, Feng Zhang, Kin Chung Lee, Hye Jin Choi, Jiandong Tong, Min Tao, Aibing Xu, Ashley Cheng, Chang-Hsien Lu, Chang-Fang Chiu, Mohamed Ibrahim Abdul Wahid, Shital Kamble, Josephine M. Norquist, Wenyan Zhong, Chen Li, Zhendong Chen
Publikováno v:
Liver Cancer (2024)
Introduction KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular
Externí odkaz:
https://doaj.org/article/af000c83c7e94d4da9def0a30952f917
Autor:
Jin Li, Shukui Qin, Lu Wen, Junsheng Wang, Wenying Deng, Weijian Guo, Tongfu Jia, Da Jiang, Guifang Zhang, Yifu He, Yi Ba, Haijun Zhong, Lin Wang, Xiaoyan Lin, Jianwei Yang, Jun Zhao, Yuxian Bai, Xiangyuan Wu, Feng Gao, Guogui Sun, Yongjuan Wu, Feng Ye, Qiong Wang, Zhong Xie, Tienan Yi, Yong Huang, Guohua Yu, Lin Lu, Ying Yuan, Wei Li, Likun Liu, Yuping Sun, Ying Sun, Lifeng Yin, Zhiguo Hou
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phas
Externí odkaz:
https://doaj.org/article/8f346a3b7ad5448abb9d1f638b99755a
Autor:
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, Jifeng Feng, Lin Wu, Dongqing Lv, Jianying Zhou, Xiaodong Zhang, Li Liu, Qitao Yu, Wangjun Liao, Yiping Zhang, Xiang Wang, Ying Cheng, Hongrui Niu, Ziping Wang, Dong Wang, Cheng Huang, Chunling Liu, Hui Zhao, Jian Feng, Jingzhang Li, Kejing Ying, Nong Yang, Shukui Qin, Jie Hu, Fei Liu, Yong Jiang, Nan Ge, Yuankai Shi
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Furmonertinib (AST2818) is a brain penetrant pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR sensitizing mutations and T790M mutation. We report the pooled central nervous system (CN
Externí odkaz:
https://doaj.org/article/110cfda033794cb7affeefa7f033dfdf